EvaluatePharma

Your commercial lens on the pharmaceutical industry
At Evaluate we collect, calibrate and connect the pharmaceutical world’s data

“Evaluate is not a package I can do without. It’s an absolute timesaver.”
Anthony M, Senior Director, Competitive Intelligence & Prospection
NOVARTIS

“Evaluate is such an important resource for us; it makes all of our lives easier.”
Vishwas S, Vice President
BANK OF AMERICA
Evaluate gives you the understanding and time you need to drive better decisions

We are data engineers who collect, calibrate and connect the financial and technical information the pharmaceutical industry needs. Our dedication to transparently aggregating commercial information from multiple sources lets you make the connections you need with confidence.

We bring the past, present and future into one view. And we’ve built up our offering from our original market-leading consensus forecasts, all the way to creating valuation models for products in development.

When you partner with Evaluate, our constantly expanding solutions and our transparent methodologies and datasets are instantly at your disposal, along with personalised support.

Evaluate gives you the time and confidence to turn understanding into insight, and insight into action.

Size new markets  Carry out market landscaping  Screen and value assets  Understand your competitors

Benchmark deals  Build forecasts and financial models  Stay abreast of industry trends

Daily analysis of key industry developments, underpinned by Evaluate’s commercial intelligence.

We don’t just tell you what’s happened – we tell you what it means for you.

Sign up at:  www.evaluate.com/vantage
Reduce the cost, time and risk of making strategic decisions

Your commercial lens
EvaluatePharma is your commercial lens on the pharmaceutical industry.

Past, present and future
Connecting past, present and future, EvaluatePharma offers a seamless view of the industry, letting you build your understanding of the commercial issues that affect strategic investment decisions.

Breadth and depth
From an overview of the broader market to a detailed product or company analysis, EvaluatePharma’s integrated platform is designed to take our clients from exploration to full understanding as quickly and accurately as possible.

Reduce the cost and risk of making decisions
With solutions suitable for asset screening, market analysis, competitive intelligence and portfolio strategy, EvaluatePharma reduces the cost, time and risk associated with making strategic decisions.

Consensus Forecasts to 2024
Our deep industry knowledge and analytical expertise allow us to create the highest quality consensus forecasts and give our clients solid benchmarks for their strategic decisions.

Our industry-leading broker coverage lets us go deeper than our competitors. With both historic and forecast sales broken down by indication, you can understand the indication-specific dynamics of each market.

Company Financials
Our extensive company-level financial information – both historic and forecast – lets you understand the leading companies in the industry in terms of their revenues and profits. Financials include profit and loss (reported and normalised), balance sheet and cash flow information, as well as valuation measures.

Our historic and forecast company models also cover product sales, therapy area sales, both pharmaceutical and non-pharmaceutical segments and portfolio performance.

Portfolio and Pipeline Analysis
We cover R&D pipeline information at each stage of the process, from research and development to filed and approved. You can cut the data with multiple lenses including phase, indication, therapy area, mechanism of action, company and technology – building a customised view of the development landscape.

You can also see the history of regulatory approvals, including FDA (USA), EMA (EU), PMDA (Japan) and ANVISA (Brazil), and key patent expiration dates.

Deals
We offer comprehensive coverage of M&A, licensing, venture financing and IPO deals in the pharmaceutical and biotech space. You can track and benchmark deals by product classification (phase of development, therapy area, technology and phase of compounds) and review deal values, upfront payments, royalties and co-promotions.

You can also evaluate any company’s M&A record, tracking the progress of their products after acquisition.

Archive Forecasts
We have the largest back catalogue of consensus drug forecasts: 485,000 forecasts covering 11,000+ drugs since January 2003, including a monthly archive of Evaluate’s Consensus Forecasts so you can see changes versus the current forecast.

We provide unique insights into equity analysts’ changing sales expectations through a drug’s life cycle. Combined with news events and Event Analyzer, we give you real-world information to monitor a drug’s progression and understand changes in its forecast commercial potential.

Event Analyzer
Our Event Analyzer reveals the news events that affect pharmaceutical and biotech company share prices and valuations. News events are curated and categorised by event type, including clinical trial results, regulatory decisions, competitor announcements, financial results, patent litigation and broker sentiment.

We calculate the share price and market capitalisation change for each event, and keep you up to date with daily and weekly round-ups of stock price winners and losers.
Connected data gives you a clearer picture

Past, present and future
Seamless commercial view of the industry
Build your understanding of the commercial issues that affect your strategic investment decisions.

Calibrated commercial data
Transparent aggregation of datasets
We calibrate different datasets to industry standards and proprietary methodologies which is why Evaluate is trusted and used industry wide.

Breadth and depth
Cut the data exactly as you need
Use any and all of a huge range of data lenses including global, region, drug, company and therapeutic area.

EvaluatePharma

- Consensus Forecasts to 2024
- Historical Sales from 1986
- Archive Sales Forecasts
- Sales by Indication
- Therapeutic Area
- Orphan Drugs
- Biosimilars

- Pharma Class
- Sales, Volume & Pricing USA, Europe, Japan & Brazil
- Company Financials
- Portfolio Analysis
- Patent Risk
- Pipeline Freshness Index
- Venture Financing & IPO

- M&A Analysis
- Company Profiles
- Daily news and Vantage
- Drug Profiles
- Tracking Drugs @FDA
- Approvals EMEA
- Uptake Curves
- Expedited Approvals
- Licensing Deals
- Event Analyzer
- R&D Pipeline
- Peer Group Analyzer
- Merge Company
- Customised reporting & easy export
- Easy integration of reports into workflows via plugins

Add more insights to your pharma subscription

Epi Analyzer  EvaluateMedTech  European Drug Forecasts to 2024  Japan Drug Forecasts to 2024
Evaluate provides trusted commercial intelligence for the pharmaceutical industry. We help our clients to refine and transform their understanding of the past, present and future of the global pharmaceutical market to drive better decisions. When you partner with Evaluate, our constantly expanding solutions and our transparent methodologies and datasets are instantly at your disposal, along with personalised, expert support.

Evaluate gives you the time and confidence to turn understanding into insight, and insight into action.

EvaluatePharma offers a global view of the pharmaceutical market’s past, present and future performance with consensus forecasts to 2024, company financials, pipelines and deals.

EvaluatePharma provides the first single view of the risk and reward of the R&D landscape with consensus forecasts, R&D costs at drug and trial level, success rates, predictive timelines and trial outcomes.

EvaluateMedTech tracks, benchmarks, and forecasts global performance for the medical device and diagnostic industry with consensus forecasts to 2024, company financials and more.

Evaluate Custom Solutions improves your strategic decision-making with customised solutions and deep insights that draw on our industry expertise and trusted commercial intelligence.

Vantage provides award-winning, thought-provoking news and insights into current and future developments in the industry, and is the only pharmaceutical news service underpinned by Evaluate’s commercial intelligence.

www.evaluate.com